{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:43:07Z","timestamp":1792514587987,"version":"4.5.0"},"reference-count":151,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Bullous pemphigoid (BP) is the most common autoimmune bullous disease, characterized by severe pruritus and skin blistering. The loss of tolerance against Collagen XVII, also referred to as BP180, is the main pathogenic event of BP, leading to production of IgG autoantibodies which mainly target the juxtamembranous extracellular non-collagenous 16th A (NC16A) domain of BP180. A complex inflammatory network is activated upon autoantibody binding to the basement membrane zone; this inflammatory loop involves the complement cascade and the release of several inflammatory cytokines, chemokines and proteases from keratinocytes, lymphocytes, mast cells and granulocytes. Collectively, these events disrupt the integrity of the dermal-epidermal junction, leading to subepidermal blistering. Recent advances have led to identify novel therapeutic targets for BP, whose management is mainly based on the long-term use of topical and systemic corticosteroids. As an example, targeting type-2 T-helper cell-associated cytokines, such as Interleukin-4 and interleukin-13 has shown meaningful clinical efficacy in case series and studies; targeting IL-17 and IL-23 has also been tried, owing to an important role of these cytokines in the chronic maintenance phase of BP. In this review article, we discuss the complex cytokine milieu that characterized BP inflammation, highlighting molecules, which are currently investigated as present and future therapeutic targets for this life-threatening disease.<\/jats:p>","DOI":"10.3389\/fmed.2023.1128154","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T04:36:51Z","timestamp":1675658211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets"],"prefix":"10.3389","volume":"10","author":[{"given":"Roberto","family":"Maglie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzan","family":"Solimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Didona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pipit\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Antiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Zenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jid.2021.04.040","article-title":"Pemphigus and pemphigoid: from disease mechanisms to druggable pathways.","author":"Ellebrecht","year":"2022","journal-title":"J Invest Dermatol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.948108","article-title":"Type XVII collagen: relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders.","volume":"13","author":"Opelka","year":"2022","journal-title":"Front Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jid.2020.08.031","article-title":"Autoantibodies to BPAG1e trigger experimental bullous pemphigoid in mice.","volume":"141","author":"Makita","year":"2021","journal-title":"J Invest Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1091\/mbc.e02-08-0548","article-title":"Interaction of the bullous pemphigoid antigen 1 (BP230) and desmoplakin with intermediate filaments is mediated by distinct sequences within their COOH terminus.","volume":"14","author":"Fontao","year":"2003","journal-title":"Mol Biol Cell."},{"key":"B5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.coph.2018.12.007","article-title":"Pharmacological advances in pemphigoid.","volume":"46","author":"Maglie","year":"2019","journal-title":"Curr Opin Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.569287","article-title":"Autoreactive peripheral blood T helper cell responses in bullous pemphigoid and elderly patients with pruritic disorders.","volume":"12","author":"Didona","year":"2021","journal-title":"Front Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jaad.2019.04.029","article-title":"Nonbullous pemphigoid: insights in clinical and diagnostic findings, treatment responses, and prognosis.","volume":"81","author":"Lamberts","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807173","article-title":"Molecular basis for global incidence of pemphigoid diseases and differences in phenotypes.","volume":"13","author":"Ahmed","year":"2022","journal-title":"Front Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/ddg.14852","article-title":"Association between bullous pemphigoid and psychiatric disorders: a systematic review and meta-analysis.","volume":"20","author":"Huang","year":"2022","journal-title":"J Dtsch Dermatol Ges."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European academy of dermatology and venereology (EADV).","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: trigger and predisposing factors.","volume":"10","author":"Moro","year":"2020","journal-title":"Biomolecules."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl Peptidase-4 inhibitor-associated bullous pemphigoid.","volume":"10","author":"Tasanen","year":"2019","journal-title":"Front Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaad.2022.02.036","article-title":"Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: results of a multicenter study.","volume":"87","author":"Salemme","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/ijd.13807","article-title":"Bullous eruption in a patient with B-cell chronic lymphocytic leukemia: a diagnostic challenge.","volume":"56","author":"Maglie","year":"2017","journal-title":"Int J Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jaad.2017.05.006","article-title":"Association of bullous pemphigoid with malignancy: a systematic review and meta-analysis.","volume":"77","author":"Atzmony","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.841506","article-title":"Bullous pemphigoid associated with COVID-19 vaccines: an italian multicentre study.","volume":"9","author":"Maronese","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e418","DOI":"10.1111\/jdv.17228","article-title":"COVID-19 pandemic and autoimmune bullous diseases: a cross-sectional study of the international pemphigus and pemphigoid foundation.","volume":"35","author":"Kasperkiewicz","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16654","article-title":"What\u2019s new in the pathogeneses and triggering factors of bullous pemphigoid.","author":"Ujiie","year":"2022","journal-title":"J Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clim.2011.10.002","article-title":"Noncollagenous 16A domain of type XVII collagen-reactive CD4+ T cells play a pivotal role in the development of active disease in experimental bullous pemphigoid model.","volume":"142","author":"Ujiie","year":"2012","journal-title":"Clin Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1172\/JCI28547","article-title":"cell control in autoimmune bullous skin disorders.","volume":"116","author":"Hertl","year":"2006","journal-title":"J Clin Invest."},{"key":"B21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/cei.12566","article-title":"T cell participation in autoreactivity to NC16a epitopes in bullous pemphigoid.","volume":"180","author":"Pickford","year":"2015","journal-title":"Clin Exp Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jid.2018.03.1515","article-title":"Identification of Immunodominant Th2-Cell epitopes in chinese patients with bullous pemphigoid.","volume":"138","author":"Zhang","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/s0923-1811(02)00067-1","article-title":"Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid.","volume":"30","author":"Giomi","year":"2002","journal-title":"J Dermatol Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/205873929901200202","article-title":"A Th2-like cytokine response is involved in bullous pemphigoid. the role of IL-4 and IL-5 in the pathogenesis of the disease.","volume":"12","author":"Feliciani","year":"1999","journal-title":"Int J Immunopathol Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.clim.2006.03.014","article-title":"Increased expression of Th2-associated chemokines in bullous pemphigoid disease. role of eosinophils in the production and release of these chemokines.","volume":"120","author":"Gounni Abdelilah","year":"2006","journal-title":"Clin Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted therapies for autoimmune bullous diseases: current status.","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs."},{"key":"B27","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaad.2019.11.023","article-title":"Clinical outcome and safety of rituximab therapy for pemphigoid diseases.","volume":"82","author":"Tovanabutra","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaad.2019.03.049","article-title":"Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients.","volume":"81","author":"Polansky","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid.","volume":"173","author":"Cho","year":"2015","journal-title":"Br J Dermatol."},{"key":"B30","article-title":"B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid.","volume":"9","author":"Berkani","year":"2019","journal-title":"Sci Rep."},{"key":"B31","first-page":"111","article-title":"B-cell targeted therapy alone may not be effective in bullous pemphigoid.","volume":"32","author":"Chee","year":"2007","journal-title":"Clin Exp Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1038\/jid.2013.236","article-title":"Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients.","volume":"133","author":"Hall","year":"2013","journal-title":"J Invest Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jid.2022.08.041","article-title":"CXCL12\/CXCR4 axis drives the chemotaxis and differentiation of B cells in bullous pemphigoid.","volume":"143","author":"Fang","year":"2023","journal-title":"J Invest Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1046\/j.1523-1747.2003.12071.x","article-title":"Memory B cells specific for the NC16A domain of the 180 kDa bullous pemphigoid autoantigen can be detected in peripheral blood of bullous pemphigoid patients and induced in vitro to synthesize autoantibodies.","volume":"120","author":"Leyendeckers","year":"2003","journal-title":"J Invest Dermatol."},{"key":"B35","article-title":"Dysfunction of CD19(+)CD24(hi)CD27(+) B regulatory cells in patients with bullous pemphigoid.","volume":"8","author":"Liu","year":"2018","journal-title":"Sci Rep."},{"key":"B36","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2133.2006.07305.x","article-title":"Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris.","volume":"155","author":"Asashima","year":"2006","journal-title":"Br J Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/exd.12421","article-title":"B-cell activating factor detected on both naive and memory B cells in bullous pemphigoid.","volume":"23","author":"Qian","year":"2014","journal-title":"Exp Dermatol."},{"key":"B38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrrheum.2012.58","article-title":"Follicular helper T cells in immunity and systemic autoimmunity.","volume":"8","author":"Craft","year":"2012","journal-title":"Nat Rev Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jaci.2020.03.036","article-title":"Targeting inducible costimulator expressed on CXCR5(+)PD-1(+) T(H) cells suppresses the progression of pemphigus vulgaris.","volume":"146","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B40","article-title":"Therapeutic targeting of follicular T cells with chimeric antigen receptor-expressing natural killer cells.","volume":"1","author":"Reighard","year":"2020","journal-title":"Cell Rep Med."},{"key":"B41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.immuni.2008.06.001","article-title":"fundamental role for interleukin-21 in the generation of T follicular helper cells.","volume":"29","author":"Vogelzang","year":"2008","journal-title":"Immunity."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068145","article-title":"Follicular helper T Cells (Tfh) and IL-21 involvement in the pathogenesis of bullous pemphigoid.","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One."},{"key":"B43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/1346-8138.15713","article-title":"Possible roles of CXCL13\/CXCR5 axis in the development of bullous pemphigoid.","volume":"48","author":"Ohuchi","year":"2021","journal-title":"J Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.jaci.2018.03.014","article-title":"Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects.","volume":"142","author":"Muramatsu","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/jdv.12091","article-title":"Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid.","volume":"28","author":"Antiga","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jdermsci.2020.08.004","article-title":"Regulatory T cell subsets in bullous pemphigoid and dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid.","volume":"100","author":"Muramatsu","year":"2020","journal-title":"J Dermatol Sci."},{"key":"B47","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/ced.13135","article-title":"regulatory cells and other lymphocyte subsets in patients with bullous pemphigoid.","volume":"42","author":"Gambichler","year":"2017","journal-title":"Clin Exp Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","article-title":"IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid.","volume":"96","author":"Chakievska","year":"2019","journal-title":"J Autoimmun."},{"key":"B49","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1600-0625.2011.01378.x","article-title":"Lesional Th17 cells and regulatory T cells in bullous pemphigoid.","volume":"20","author":"Arakawa","year":"2011","journal-title":"Exp Dermatol."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/srep18001","article-title":"Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome.","volume":"5","author":"Plee","year":"2015","journal-title":"Sci Rep."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00701","article-title":"NET formation in bullous pemphigoid patients with relapse is modulated by IL-17 and IL-23 Interplay.","volume":"10","author":"Giusti","year":"2019","journal-title":"Front Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid.","volume":"134","author":"Le Jan","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01972","article-title":"IL-23\/IL-17 Axis Activates IL-1beta-Associated inflammasome in macrophages and generates an auto-inflammatory response in a subgroup of patients with bullous pemphigoid.","volume":"10","author":"Le Jan","year":"2019","journal-title":"Front Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/ddg.14291","article-title":"Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid.","volume":"18","author":"Holtsche","year":"2020","journal-title":"J Dtsch Dermatol Ges."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1111\/ajd.13803","article-title":"Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report.","volume":"63","author":"Yun","year":"2022","journal-title":"Australas J Dermatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1111\/1346-8138.16189","article-title":"Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis.","volume":"49","author":"Lu","year":"2022","journal-title":"J Dermatol."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16559","article-title":"Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid.","author":"Xiao","year":"2022","journal-title":"J Dermatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40257-022-00719-7","article-title":"Management of coexisting bullous pemphigoid and psoriasis: a review.","volume":"23","author":"Hsieh","year":"2022","journal-title":"Am J Clin Dermatol."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology.","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol."},{"key":"B60","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00105-019-04509-x","article-title":"[Pharmacology of Janus kinase inhibitors].","volume":"70","author":"Solimani","year":"2019","journal-title":"Hautarzt."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010323","article-title":"Expression of the selected proteins of JAK\/STAT signaling pathway in diseases with oral mucosa involvement.","volume":"24","author":"Ociepa","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15754","article-title":"Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib.","volume":"35","author":"Xiao","year":"2022","journal-title":"Dermatol Ther."},{"key":"B63","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jid.2017.09.026","article-title":"Increasing the complement of therapeutic options in bullous pemphigoid.","volume":"138","author":"Kushner","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/exd.12146","article-title":"Bullous pemphigoid: role of complement and mechanisms for blister formation within the lamina lucida.","volume":"22","author":"Iwata","year":"2013","journal-title":"Exp Dermatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bjd.14822","article-title":"Complement in bullous pemphigoid: results from a large observational study.","volume":"176","author":"Romeijn","year":"2017","journal-title":"Br J Dermatol."},{"key":"B66","first-page":"548","article-title":"Complement immunofluorescent staining in bullous pemphigoid.","volume":"74","author":"Jordon","year":"1969","journal-title":"J Lab Clin Med."},{"key":"B67","first-page":"96","article-title":"Immunopathological techniques in the diagnosis of bullous disorders.","volume":"151","author":"Black","year":"1989","journal-title":"Acta Derm Venereol Suppl (Stockh)."},{"key":"B68","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/bjd.18229","article-title":"Anticomplement therapy in bullous pemphigoid.","volume":"181","author":"Hashimoto","year":"2019","journal-title":"Br J Dermatol."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02687","article-title":"Complement-Activating capacity of autoantibodies correlates with disease activity in bullous pemphigoid patients.","volume":"9","author":"Chiorean","year":"2018","journal-title":"Front Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/jdv.15325","article-title":"Characteristics of IgG subclasses and complement deposition in BP230-type bullous pemphigoid.","volume":"33","author":"Zheng","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1172\/JCI17891","article-title":"Role of different pathways of the complement cascade in experimental bullous pemphigoid.","volume":"116","author":"Nelson","year":"2006","journal-title":"J Clin Invest."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid.","volume":"95","author":"Liu","year":"1995","journal-title":"J Clin Invest."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1016\/j.jid.2019.04.025","article-title":"Specific inhibition of the classical complement pathway prevents C3 deposition along the dermal-epidermal junction in bullous pemphigoid.","volume":"139","author":"Freire","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1074\/jbc.M111.221036","article-title":"The C5a receptor on mast cells is critical for the autoimmune skin-blistering disease bullous pemphigoid.","volume":"286","author":"Heimbach","year":"2011","journal-title":"J Biol Chem."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00535","article-title":"Specific inhibition of complement activation significantly ameliorates autoimmune blistering disease in mice.","volume":"9","author":"Mihai","year":"2018","journal-title":"Front Immunol."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00488","article-title":"Tissue destruction in bullous pemphigoid can be complement independent and may be mitigated by C5aR2.","volume":"9","author":"Karsten","year":"2018","journal-title":"Front Immunol."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.942493","article-title":"Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients.","volume":"13","author":"Emtenani","year":"2022","journal-title":"Front Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.jid.2016.12.021","article-title":"The Leukotriene B(4) and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita.","volume":"137","author":"Sezin","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.128239","article-title":"Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease.","volume":"4","author":"Sezin","year":"2019","journal-title":"JCI Insight."},{"key":"B80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.smim.2018.03.002","article-title":"The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin.","volume":"37","author":"Sadik","year":"2018","journal-title":"Semin Immunol."},{"key":"B81","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous pemphigoid autoantibodies directly induce blister formation without complement activation.","volume":"193","author":"Ujiie","year":"2014","journal-title":"J Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.4049\/jimmunol.1003402","article-title":"Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner.","volume":"188","author":"Natsuga","year":"2012","journal-title":"J Immunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1365-4632.2008.03361.x","article-title":"The predominance of IgG4 in prodromal bullous pemphigoid.","volume":"47","author":"Lamb","year":"2008","journal-title":"Int J Dermatol."},{"key":"B84","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jaut.2016.06.019","article-title":"IgG4 autoantibodies are inhibitory in the autoimmune disease bullous pemphigoid.","volume":"73","author":"Zuo","year":"2016","journal-title":"J Autoimmun."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.973702","article-title":"The relevance of complement in pemphigoid diseases: a critical appraisal.","volume":"13","author":"Papara","year":"2022","journal-title":"Front Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/jid.2008.305","article-title":"IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment.","volume":"129","author":"Iwata","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B87","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1523-1747.2000.00141.x","article-title":"Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes.","volume":"115","author":"Schmidt","year":"2000","journal-title":"J Invest Dermatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1111\/bjd.15924","article-title":"IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants.","volume":"177","author":"Freire","year":"2017","journal-title":"Br J Dermatol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1172\/JCI119639","article-title":"A major role for neutrophils in experimental bullous pemphigoid.","volume":"100","author":"Liu","year":"1997","journal-title":"J Clin Invest."},{"key":"B90","doi-asserted-by":"publisher","first-page":"368","DOI":"10.23736\/S0031-0808.20.03997-X","article-title":"Eosinophils in bullous pemphigoid.","volume":"63","author":"Jones","year":"2021","journal-title":"Panminerva Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"544","DOI":"10.5021\/ad.2018.30.5.544","article-title":"Circulating eosinophil and neutrophil counts correlate with disease severity in bullous pemphigoid.","volume":"30","author":"Park","year":"2018","journal-title":"Ann Dermatol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1172\/JCI3693","article-title":"A critical role for neutrophil elastase in experimental bullous pemphigoid.","volume":"105","author":"Liu","year":"2000","journal-title":"J Clin Invest."},{"key":"B93","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1087-0024.2004.00841.x","article-title":"Bullous pemphigoid: using animal models to study the immunopathology.","volume":"9","author":"Liu","year":"2004","journal-title":"J Investig Dermatol Symp Proc."},{"key":"B94","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jid.2022.07.019","article-title":"Absence of NC14A domain of COLXVII\/BP180 in mice results in IL-17?associated skin inflammation.","volume":"143","author":"Lindgren","year":"2022","journal-title":"J Invest Dermatol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.matbio.2011.09.003","article-title":"Neutrophil elastase cleaves the murine hemidesmosomal protein BP180\/type XVII collagen and generates degradation products that modulate experimental bullous pemphigoid.","volume":"31","author":"Lin","year":"2012","journal-title":"Matrix Biol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1046\/j.0022-202x.2001.01521.x","article-title":"Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid.","volume":"117","author":"Verraes","year":"2001","journal-title":"J Invest Dermatol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.jid.2021.04.009","article-title":"Dapsone suppresses disease in preclinical murine models of pemphigoid diseases.","volume":"141","author":"Murthy","year":"2021","journal-title":"J Invest Dermatol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1111\/exd.14209","article-title":"Distinct compartmentalization of immune cells and mediators characterizes bullous pemphigoid disease.","volume":"29","author":"Margaroli","year":"2020","journal-title":"Exp Dermatol."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3771","article-title":"Immunomodulator Galectin-9 is increased in blood and skin of patients with bullous pemphigoid.","volume":"101","author":"Pruessmann","year":"2021","journal-title":"Acta Derm Venereol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/exd.13157","article-title":"A possible interaction between periostin and CD163(+) skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid.","volume":"26","author":"Fujimura","year":"2017","journal-title":"Exp Dermatol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/jid.2011.251","article-title":"High levels of CCL26 in blister fluid and sera of patients with bullous pemphigoid.","volume":"132","author":"Kagami","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B102","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.autrev.2019.03.009","article-title":"Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid.","volume":"18","author":"Kowalski","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B103","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00403-021-02253-8","article-title":"Characterizing the proteome of bullous pemphigoid blister fluid utilizing tandem mass tag labeling coupled with LC-MS\/MS.","volume":"314","author":"Solimani","year":"2022","journal-title":"Arch Dermatol Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1046\/j.1365-2133.2000.03599.x","article-title":"Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia.","volume":"143","author":"Wakugawa","year":"2000","journal-title":"Br J Dermatol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1046\/j.1365-2133.2000.03894.x","article-title":"High levels of interleukin-8, soluble CD4 and soluble CD8 in bullous pemphigoid blister fluid. The relationship between local cytokine production and lesional T-cell activities.","volume":"143","author":"Sun","year":"2000","journal-title":"Br J Dermatol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jdermsci.2008.10.012","article-title":"Increased CCL1 levels in the sera and blister fluid of patients with bullous pemphigoid.","volume":"54","author":"Miyagaki","year":"2009","journal-title":"J Dermatol Sci."},{"key":"B107","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2249.2011.04464.x","article-title":"Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid.","volume":"166","author":"Gunther","year":"2011","journal-title":"Clin Exp Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/all.13131","article-title":"Evidence for a role of eosinophils in blister formation in bullous pemphigoid.","volume":"72","author":"de Graauw","year":"2017","journal-title":"Allergy."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100145R","article-title":"Neutrophil extracellular traps contribute to immune dysregulation in bullous pemphigoid via inducing B-cell differentiation and antibody production.","volume":"35","author":"Fang","year":"2021","journal-title":"FASEB J."},{"key":"B110","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2340\/00015555-2951","article-title":"Eosinophils are a major source of interleukin-31 in bullous pemphigoid.","volume":"98","author":"Rudrich","year":"2018","journal-title":"Acta Derm Venereol."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00201","article-title":"The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease.","volume":"5","author":"Amber","year":"2018","journal-title":"Front Med (Lausanne)."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","article-title":"Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid.","volume":"138","author":"Lin","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/all.13376","article-title":"Monocytes enhance neutrophil-induced blister formation in an ex vivo model of bullous pemphigoid.","volume":"73","author":"de Graauw","year":"2018","journal-title":"Allergy."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20604-3","article-title":"Granzyme B inhibition reduces disease severity in autoimmune blistering diseases.","volume":"12","author":"Hiroyasu","year":"2021","journal-title":"Nat Commun."},{"key":"B115","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaci.2016.08.012","article-title":"Bullous pemphigoid outcome is associated with CXCL10-induced matrix metalloproteinase 9 secretion from monocytes and neutrophils but not lymphocytes.","volume":"139","author":"Riani","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1159\/000365946","article-title":"Comparison of CD163+ CD206+ M2 macrophages in the lesional skin of bullous pemphigoid and pemphigus vulgaris: the possible pathogenesis of bullous pemphigoid.","volume":"229","author":"Furudate","year":"2014","journal-title":"Dermatology."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01858","article-title":"Blister fluid induces MMP-9-Associated M2-Type macrophages in bullous pemphigoid.","volume":"10","author":"Riani","year":"2019","journal-title":"Front Immunol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/exd.13779","article-title":"Minocycline decreases Th2 chemokines from M2 macrophages: possible mechanisms for the suppression of bullous pemphigoid by traditional bullous disease drugs.","volume":"27","author":"Tanita","year":"2018","journal-title":"Exp Dermatol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","article-title":"Pathophysiologic mechanisms of itch in bullous pemphigoid.","volume":"83","author":"Hashimoto","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.4049\/jimmunol.169.7.3987","article-title":"Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation.","volume":"169","author":"Chen","year":"2002","journal-title":"J Immunol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1172\/JCI11494","article-title":"Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid.","volume":"108","author":"Chen","year":"2001","journal-title":"J Clin Invest."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.70","article-title":"Mast cell-deficient mice Mcpt5Cre\/Dicer (fl\/fl) redefine the role of mast cells in experimental bullous pemphigoid.","volume":"2","author":"Nsiah-Dosu","year":"2022","journal-title":"Skin Health Dis."},{"key":"B123","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jaad.2020.02.058","article-title":"Bullous pemphigoid: rituximab to the rescue?","volume":"82","author":"Heymann","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B124","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjd.19890","article-title":"Mortality and clinical response of patients with bullous pemphigoid treated with rituximab.","volume":"185","author":"Yoo","year":"2021","journal-title":"Br J Dermatol."},{"key":"B125","doi-asserted-by":"crossref","first-page":"T62","DOI":"10.1016\/j.ad.2021.10.018","article-title":"Low-Dose rituximab for bullous pemphigoid. protocol and single-center experience.","volume":"114","author":"Suarez-Carantona","year":"2023","journal-title":"Actas Dermosifiliogr."},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16668","article-title":"Three cases of refractory bullous pemphigoid in the elderly treated successfully with ultra-low-dose rituximab.","author":"Chen","year":"2022","journal-title":"J Dermatol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jid.2018.02.020","article-title":"Modes of action of intravenous immunoglobulin in bullous pemphigoid.","volume":"138","author":"Li","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid.","volume":"85","author":"Amagai","year":"2017","journal-title":"J Dermatol Sci."},{"key":"B129","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1046\/j.1468-3083.2003.00714.x","article-title":"Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid.","volume":"17","author":"Sami","year":"2003","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1067\/mjd.2000.112288","article-title":"Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data.","volume":"44","author":"Engineer","year":"2001","journal-title":"J Am Acad Dermatol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bjd.20939","article-title":"Targeting the neonatal Fc receptor in pemphigus: safety first.","volume":"186","author":"Micevic","year":"2022","journal-title":"Br J Dermatol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial.","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol."},{"key":"B133","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15946","article-title":"Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid.","volume":"35","author":"Vassallo","year":"2022","journal-title":"Dermatol Ther."},{"key":"B134","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4103\/0378-6323.183628","article-title":"Bullous pemphigoid successfully treated with omalizumab.","volume":"82","author":"Gonul","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B135","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/12034754221089267","article-title":"Omalizumab for the treatment of bullous pemphigoid: a systematic review of efficacy and safety.","volume":"26","author":"D\u2019Aguanno","year":"2022","journal-title":"J Cutan Med Surg."},{"key":"B136","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/ejhpharm-2020-002418","article-title":"Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient.","volume":"28","author":"Navarro-Trivino","year":"2021","journal-title":"Eur J Hosp Pharm."},{"key":"B137","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1684\/ejd.2019.3499","article-title":"Dramatic exacerbation of bullous pemphigoid following rituximab and successful treatment with omalizumab.","volume":"29","author":"Maglie","year":"2019","journal-title":"Eur J Dermatol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1111\/jdv.17229","article-title":"Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities.","volume":"35","author":"De","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review.","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol."},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01919","article-title":"Effects of omalizumab on fcepsilonRI and IgE expression in lesional skin of bullous pemphigoid.","volume":"10","author":"Seyed Jafari","year":"2019","journal-title":"Front Immunol."},{"key":"B141","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/bjd.18156","article-title":"Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low-molecular-weight heparin tinzaparin sodium.","volume":"181","author":"Gutjahr","year":"2019","journal-title":"Br J Dermatol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jamadermatol.2022.1156","article-title":"Evaluation of nomacopan for treatment of bullous pemphigoid: a phase 2a nonrandomized controlled trial.","volume":"158","author":"Sadik","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B143","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid.","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/1346-8138.16428","article-title":"Treatment of bullous pemphigoid with dupilumab: dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines.","volume":"49","author":"Takamura","year":"2022","journal-title":"J Dermatol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series.","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15648","article-title":"Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol Ther."},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738907","article-title":"Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid.","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol."},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611549","article-title":"Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid.","volume":"11","author":"Seyed Jafari","year":"2020","journal-title":"Front Immunol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1111\/jdv.18673","article-title":"Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab.","volume":"37","author":"Baffa","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.5070\/D328257396","article-title":"A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab.","volume":"15","author":"Bruni","year":"2022","journal-title":"Dermatol Online J."},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report.","volume":"35","author":"Pop","year":"2022","journal-title":"Dermatol Ther."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1128154\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T04:37:15Z","timestamp":1675658235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1128154\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":151,"alternative-id":["10.3389\/fmed.2023.1128154"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1128154","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"article-number":"1128154"}}